Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Nichi-Iko Pharmaceutical Co Ltd
Net Income (Common)
Nichi-Iko Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
Net Income (Common)
-¥105B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Net Income (Common)
¥178.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
2%
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Net Income (Common)
¥186.1B
|
CAGR 3-Years
38%
|
CAGR 5-Years
23%
|
CAGR 10-Years
5%
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Net Income (Common)
¥121.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-4%
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Net Income (Common)
¥325.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
29%
|
CAGR 10-Years
20%
|
|
Astellas Pharma Inc
TSE:4503
|
Net Income (Common)
¥37.3B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-9%
|
See Also
What is Nichi-Iko Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
-105B
JPY
Based on the financial report for Mar 31, 2022, Nichi-Iko Pharmaceutical Co Ltd's Net Income (Common) amounts to -105B JPY.
What is Nichi-Iko Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
-2 412%
Over the last year, the Net Income (Common) growth was -2 412%.